Company Description
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs.
The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology.
Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer.
The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment.
Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Thomas Jensen |
Contact Details
Address: 24 School Street, 2nd Floor Boston, Massachusetts 02108 United States | |
| Phone | 401 426 4664 |
| Website | allarity.com |
Stock Details
| Ticker Symbol | ALLR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $0.00 |
| CIK Code | 0001860657 |
| CUSIP Number | 016744500 |
| ISIN Number | US0167445008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas H. Jensen | Founder, Chief Executive Officer and Director |
| Dr. Jeremy R. Graff Ph.D. | President and Chief Development Officer |
| Dr. Steen Meier Knudsen Ph.D. | Founder and Chief Scientific Officer |
| Jeffrey S. Ervin M.B.A. | Chief Financial Officer |
| Dr. Jose L. Iglesias M.D. | Consultant Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | 8-K | Current Report |
| Apr 27, 2026 | 424B3 | Prospectus |
| Apr 24, 2026 | EFFECT | Notice of Effectiveness |
| Apr 24, 2026 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 22, 2026 | 8-K | Current Report |
| Apr 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 1, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 9, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 8-K | Current Report |